Amineptine

Amineptine

Clinical data
Trade names	Survector
Routes of administration	Oral
ATC code	N06AA19 (WHO)
Legal status
Legal status	AU: Unscheduled CA: Schedule III DE: Anlage II (Prohibited) UK: Class C UN: Schedule II
Pharmacokinetic data
Metabolism	Hepatic
Biological half-life	48 mins (original drug) 2.5 hours (metabolites)
Excretion	Renal
Identifiers
IUPAC name 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)amino]heptanoic acid
CAS Number	57574-09-1 Y
PubChem (CID)	34870
DrugBank	DB04836 Y
ChemSpider	32091 Y
UNII	27T1I13L6G Y
KEGG	D07335 Y
ChEBI	CHEBI:32499 Y
ChEMBL	CHEMBL418995 Y
ECHA InfoCard	100.055.271
Chemical and physical data
Formula	C22H28NO2
Molar mass	338.4653 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(CCCCCCNC1C2=C(CCC3=C1C=CC=C3)C=CC=C2)O
InChI InChI=1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25) Y Key:ONNOFKFOZAJDHT-UHFFFAOYSA-N Y

Amineptine was developed by the French Society of Medical research in the 1960s. Under the trade-names (Survector, Maneon, Directim, Neolior, Provector, Viaspera) amineptine was used as an atypical tricyclic antidepressant (TCA) that selectively inhibits the reuptake of dopamine and to a lesser extent norepinephrine, in turn producing an antidepressant effect.

Introduced in France in 1978 by the pharmaceutical company Servier and marketed under the trade name Survector, amineptine soon gained a reputation for abuse due to its short-lived, but pleasant, stimulant effect experienced by some patients. (This is to be distinguished from its antidepressant effect, which appears in approximately seven days after commencing treatment.)

After its release into the European market, cases of hepatotoxicity emerged, some serious. This, along with the potential for abuse, led to the suspension of the French marketing authorization for Survector in 1999.

Amineptine was never approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States, meaning that it is not legal to market or sell amineptine for any medical uses in the US.

Amineptine was approved in France for severe clinical depression of endogenous origin in 1978.

Parkinson's Disease, amotivational syndromes, ADHD (Attention Deficit Hyperactivity Disorder)

Amineptine inhibits the reuptake of dopamine and, to a lesser extent, of norepinephrine. There is also some evidence that amineptine additionally acts to selectively induce the presynaptic release of dopamine. In addition to its catecholaminergic actions, amineptine is a very weak anticholinergic and antihistamine.